Canakinumab in autoimmune and autoinflammatory rheumatic diseases

Bibliography

• March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985;315:641-7
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-25
   PubMed Web of Science ®Google Scholar
• Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6
   PubMed Web of Science ®Google Scholar
• Carter DB, Deibel MR Jr, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8
   PubMed Web of Science ®Google Scholar
• Sims JE, Gayle MA, Slack JL, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993;90:6155-9
   PubMed Web of Science ®Google Scholar
• Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012;5:e1-18
   Google Scholar
• Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007;14:1583-9
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-9
   PubMed Web of Science ®Google Scholar
• Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007;104:11742-7
   PubMed Web of Science ®Google Scholar
• Sandell LJ, Xing X, Franz C, et al. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 2008;16:1560-71
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Tahiri K, Frazier A, et al. Hes1, a new target for interleukin 1beta in chondrocytes. Ann Rheum Dis 2010;69(8):1488-94
   PubMed Web of Science ®Google Scholar
• Kutukculer N, Caglayan S, Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17:288-92
   PubMed Web of Science ®Google Scholar
• Madson KL, Moore TL, Lawrence JM, et al. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994;21:2359-63
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A, Notarangelo LD, et al. Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis. J Rheumatol 1986;13:598-603
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41
   PubMed Web of Science ®Google Scholar
• Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006;116:2262-71
   PubMed Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. MAbs 2010;2:3-13
   PubMed Web of Science ®Google Scholar
• Ruperto N, et al. Baseline characteristics of patients with active systemic JIA successfully discontinuing corticosteroid while receiving canakinumab: secondary analysis from a pivotal Phase 3 trial [abstract]. EULAR Annual European Congress of Rheumatology; 12 – 15 June 2013; Madrid, Spain
   Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78
   PubMed Web of Science ®Google Scholar
• Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005;17:612-16
   PubMed Web of Science ®Google Scholar
• Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis 2006;64:72-6
   PubMedGoogle Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2385-95
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum 2012;42(2):201-5
   PubMed Web of Science ®Google Scholar
• Petryna Olga CJ, Apostolos K, Petros E. Successful use of the IL-1 trap rilonacept in adult-onset Still’s disease refractory to anakinra [abstract]. Ann Rheum Dis 2011;70(Suppl 3)
   Google Scholar
• Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13:R202
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ilaris: summary of product characteristics. Aailable from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf
   Google Scholar
• FDA label information Ilaris (canakinumab). Aailable from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf
   Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and effi cacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:2095-102
   PubMed Web of Science ®Google Scholar
• Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013;15:R33
   PubMed Web of Science ®Google Scholar
• Curran MP. Canakinumab: in patients with cryopyrin-associated periodic syndromes. BioDrugs 2012;26:53-9
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Piram M. Targeting interleukin-1beta in cAPS (cryopyrin-associated periodic) syndrome: what did we learn? Autoimmun Rev 2012;12:77-80
   PubMed Web of Science ®Google Scholar
• Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012;71:1177-82
   PubMed Web of Science ®Google Scholar
• Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619-33
   PubMed Web of Science ®Google Scholar
• Olszewski WL, Pazdur J, Kubasiewicz E, et al. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum 2001;44(3):541-9
   PubMedGoogle Scholar
• Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003;42(Suppl 2):ii3-10
   PubMedGoogle Scholar
• Lettesjo H, Nordstrom E, Strom H, et al. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol 1998;48:286-92
   PubMed Web of Science ®Google Scholar
• Holt I, Cooper RG, Denton J, et al. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 1992;31:725-33
   PubMedGoogle Scholar
• Kahle P, Saal JG, Schaudt K, et al. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731-4
   PubMed Web of Science ®Google Scholar
• Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics 2010;4:131-8
   PubMedGoogle Scholar
• Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206:1029-36
   PubMed Web of Science ®Google Scholar
• Ait-Oudhia S, Lowe PJ, Mager DE. Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL-1beta kinetics. CPT Pharmacometrics Syst Pharmacol 2012;1:e5
   PubMedGoogle Scholar
• Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011;12:153
   PubMed Web of Science ®Google Scholar
• So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62(10):3064-76
   PubMed Web of Science ®Google Scholar
• Amaral FA, Costa VV, Tavares LD, et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum 2012;64:474-84
   PubMed Web of Science ®Google Scholar